Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- May 15
- 1 min read
13/05/2026
Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis (Ref)
Qureight, an imaging CRO and Mediar Therapeutics announced that Qureight’s AI-powered 3D quantitative imaging analytics platform and services will be used to support Mediar’s Phase 2, EncompaSSc trial evaluating MTX-474 (a first in class human mAb, that inhibits EphrinB2) in people with diffuse cutaneous Systemic Sclerosis (dcSSc).
Qureight’s AI-powered 3D quantitative imaging analytics platform and services will be used to analyse HRCT images taken to evaluate changes in compartment-specific lung biomarkers in people with dcSSc.
Qureight’s imaging models, including Glass8™, Fibr8™, Vascul8™, Air8™ and Lung8™, enable precise compartment-specific assessment of inflammatory, fibrotic, vascular and airway-related changes in the lungs, supporting deeper understanding of disease progression and therapeutic response in Systemic Sclerosis.
